Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kirsi Talala

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Cancers|January 27, 2021
Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and ValidationSubas Neupane, Jaakko Nevalainen, Jani Raitanen, et al.
British Journal of Cancer|May 3, 2022
Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate CancerJukka K Salminen, Aino Mehtola, Kirsi Talala, et al.
Cancer Epidemiology|September 17, 2016
Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate CancerTuomas P Kilpeläinen, Tuukka Mäkinen, Pekka J Karhunen, et al.
International Journal of Cancer|February 26, 2021
Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate CancerJukka K Salminen, Viivu Kuoppamäki, Kirsi Talala, et al.
The Journal of Urology|January 21, 2017
Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate CancerTuomas P Kilpeläinen, Dimitri Pogodin-Hannolainen, Kimmo Kemppainen, et al.
JAMA Oncology|November 24, 2021
Outcomes of Screening for Prostate Cancer Among Men Who Use StatinsArla Vettenranta, Teemu J Murtola, Jani Raitanen, et al.
Plos One|October 7, 2025
SNP genotypes in CYP2C9 and VKORC1 genes do not affect prostate cancer or cancer mortality among warfarin users in Finnish prostate cancer patientsTeemu J Murtola, Kaisa M Skantsi, Aino Siltari, et al.
BJU International|May 10, 2024
Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate CancerNiko Pasanen, Kirsi Talala, Sebastiaan Remmers, et al.
British Journal of Cancer|August 21, 2015
Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPCNora Pashayan, Paul Dp Pharoah, Johanna Schleutker, et al.
European Urology Focus|November 16, 2017
A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate CancerMelissa Assel, Liisa Sjöblom, Teemu J Murtola, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Cancers|January 27, 2021
Prognostic Index for Predicting Prostate Cancer Survival in a Randomized Screening Trial: Development and ValidationSubas Neupane, Jaakko Nevalainen, Jani Raitanen, et al.
British Journal of Cancer|May 3, 2022
Anti-epileptic drugs and prostate cancer-specific mortality compared to non-users of anti-epileptic drugs in the Finnish Randomized Study of Screening for Prostate CancerJukka K Salminen, Aino Mehtola, Kirsi Talala, et al.
Cancer Epidemiology|September 17, 2016
Estimating bias in causes of death ascertainment in the Finnish Randomized Study of Screening for Prostate CancerTuomas P Kilpeläinen, Tuukka Mäkinen, Pekka J Karhunen, et al.
International Journal of Cancer|February 26, 2021
Antiepileptic drugs and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate CancerJukka K Salminen, Viivu Kuoppamäki, Kirsi Talala, et al.
The Journal of Urology|January 21, 2017
Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate CancerTuomas P Kilpeläinen, Dimitri Pogodin-Hannolainen, Kimmo Kemppainen, et al.
JAMA Oncology|November 24, 2021
Outcomes of Screening for Prostate Cancer Among Men Who Use StatinsArla Vettenranta, Teemu J Murtola, Jani Raitanen, et al.
Plos One|October 7, 2025
SNP genotypes in CYP2C9 and VKORC1 genes do not affect prostate cancer or cancer mortality among warfarin users in Finnish prostate cancer patientsTeemu J Murtola, Kaisa M Skantsi, Aino Siltari, et al.
BJU International|May 10, 2024
Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate CancerNiko Pasanen, Kirsi Talala, Sebastiaan Remmers, et al.
British Journal of Cancer|August 21, 2015
Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPCNora Pashayan, Paul Dp Pharoah, Johanna Schleutker, et al.
European Urology Focus|November 16, 2017
A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate CancerMelissa Assel, Liisa Sjöblom, Teemu J Murtola, et al.
Pageof 7